$TAUG Executes Commercialization and Distribution Agreement

Tauriga Sciences, Inc. (OTCQB:  TAUG) or (“Tauriga” or “the Company”), an internationally diversified life sciences company, today announced that its wholly owned subsidiary Pilus Energy LLC (“Pilus Energy”) has executed a Commercialization and Distribution Agreement (“the Agreement”) with Singapore based Naturo Energy Pte. Ltd. (“Naturo Energy”).  The Agreement will be exclusive for the continent of Asia and focus on the commercialization of U.S. Patent # 8,354,267 Titled “Microbial Fuel Cell” which was granted to Bacterial Robotics, LLC (“Bacterial Robotics”) on January 15, 2013.  Recall that on January 28, 2014 Tauriga Sciences acquired 100% of the outstanding shares of Pilus Energy (inclusive of U.S. Patent # 8,354,267) from Bacterial Robotics (now known as Microbial Robotics).  Naturo Energy has committed to Pilus Energy the following engagement activities: seek Research Collaboration with local universities, seek Commercial Collaboration with leading global providers of services and products for the water and wastewater industry, and seek Test-Bedding opportunities with local wastewater treatment plants.

Commenting on this commercialization agreement, Tauriga’s CEO Mr. Seth M. Shaw stated, “The future success of Pilus Energy is of great importance to the future of Tauriga Sciences, Inc. and its shareholders.  The execution of this agreement with Naturo Energy provides Pilus Energy with a credible entry to the Asian marketplace and the requisite resources to potentially augment the commercialization process.  In addition the Company has reached out to Metropolitan Sewer District of Greater Cincinnati and is working diligently towards recommencing the testing that was put on hold during Calendar Year 2014.”

Naturo Energy’s Chief Executive Officer Ms. Wendy Koo expressed, “After careful review and consideration, Naturo Energy has decided to endorse Pilus Energy to the Asian marketplace.  The determining factors were the merits of Pilus Energy’s intellectual property and the potential scalability of the technology to address industrial wastewater treatment needs. Singapore is recognised as a ‘Global Hydrohub’ with about 130 water companies. These companies represent the entire value chain of the water industry, spanning from upstream component players (e.g.membrane and pumps manufacturers), equipment OEMs, and system integrators, to downstream EPC players and project developers. Singapore is an ideal strategic springboard for environmental and water companies looking to serve the region and Naturo Energy is proud of our numerous industry relationships and alliances.”

About TAURIGA SCIENCES, INC.:

Tauriga Sciences, Inc. (OTCQB:  TAUG) is a diversified life sciences company focused on generating profitable revenues through its present and future holdings.  The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms.  Please visit the Company’s corporate website at www.tauriga.com

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Food and Drug Administration Disclaimer:  None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration.  Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.

CONTACT:

Mr. Seth M. Shaw,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
New York City: + 1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@tauriga.com

or

Ghalia Lahlou
Interim Chief Financial Officer
Tauriga Scienes, Inc.
Montreal:  +1-514-840-3697
Email:  glahlou@tauriga.com